PGT embryo biopsy risks: damage, sampling and test limitations

PGT decisions involve the procedure, the information produced and the options after a result. These issues should be discussed separately with the treating team.

Biopsy can damage an embryo

Embryo biopsy can cause damage and affect further development. HFEA’s PGT-A patient information describes this risk. This UK regulator source supports the existence of risk; it does not establish one damage percentage for Thai clinics. Ask for data tied to a defined procedure, population and outcome.

A result describes the tested sample

Laboratory limitations and sampling need explanation before consent. For mosaic PGT-A findings, reporting categories and thresholds may differ between laboratories: ASRM committee opinion, 2023, Fertility and Sterility 120:973–982. This professional guidance is not a Thai laboratory survey or a personal risk estimate.

Ask for evidence that matches the question

• How does the laboratory define biopsy-related damage, and are freezing, warming and repeat biopsy recorded separately?
• What period, sample size and embryo group are included in its own outcome data?
• What can the proposed test detect, and what remains outside its scope?
• How are no-result and mosaic findings reported, explained and managed before any decision?
• Who can provide qualified genetic counselling and discuss any follow-up testing?

A single accuracy percentage cannot substitute for the test’s validation scope. This page does not prescribe whether to test, transfer, retest or discard an embryo.

Use the laboratory risk discussion worksheet.

Information boundary: This is a planning aid. The treating clinician and laboratory explain medical findings, treatment and consent. Confirm current eligibility and administrative requirements with the responsible institution. This page does not assess an individual case.

Sources checked 15 October 2026. No clinical review by a named professional is claimed.